by admin | Mar 16, 2023 | Press Releases
– OMNIA-2 is a Phase I/II study evaluating ANV419 as monotherapy and in combination with daratumumab, or lenalidomide plus dexamethasone in patients with relapsed/refractory multiple myeloma – Basel, March 16, 2023 – Anaveon, a clinical stage,... 
by admin | Nov 30, 2022 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced the appointment of Dr Eduard Gasal as Chief Medical Officer (CMO). 
by admin | Nov 10, 2022 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced updated clinical data from the ongoing Phase I study of ANV419 in patients with solid tumors at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA 
by admin | Oct 31, 2022 | Press Releases
Anaveon, a clinical stage, immuno-oncology company, today announced that it will present two posters on its lead program ANV419 at the upcoming Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, being held from November 8–12, 2022, at the Boston Convention and Exhibition Center in Boston, MA. 
by admin | Sep 10, 2022 | Press Releases
– ANV419 is well-tolerated at high doses and demonstrates notable safety with strong pharmacodynamic effects and excellent IL-2R-beta-gamma selectivity – – A Phase II program of ANV419 has been initiated in Melanoma and multiple combination trials,... 
Anaveon announces presentation of a novel development compound at the 2023 American Association for Cancer Research Annual MeetingMarch 23, 2023
Anaveon announces first patient dosed with ANV419 in a Phase I/II Study of ANV419 in patients with multiple myelomaMarch 16, 2023
Anaveon doses first patient in a Phase I/II Study of ANV419 as monotherapy or in combination with check point inhibitors in patients with advanced melanomaFebruary 2, 2023